These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 12955572)

  • 21. Translational and clinical studies of target-based cancer therapy.
    Saijo N; Nishio K; Tamura T
    Int J Clin Oncol; 2003 Aug; 8(4):187-92. PubMed ID: 12955572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective.
    Perry WL; Weitzman A
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):199-202, 237-8. PubMed ID: 16166991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The convergence of cancer prevention and therapy in early-phase clinical drug development.
    Abbruzzese JL; Lippman SM
    Cancer Cell; 2004 Oct; 6(4):321-6. PubMed ID: 15488755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenome-derived drugs: recent advances and future perspectives.
    Vogiatzi P; Aimola P; Scarano MI; Claudio PP
    Drug News Perspect; 2007 Dec; 20(10):627-33. PubMed ID: 18301797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular target-based cancer therapy: tyrosine kinase inhibitors.
    Tamura K; Fukuoka M
    Int J Clin Oncol; 2003 Aug; 8(4):207-11. PubMed ID: 12955575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The contemporary drug development process: advances and challenges in preclinical and clinical development.
    Garrett MD; Walton MI; McDonald E; Judson I; Workman P
    Prog Cell Cycle Res; 2003; 5():145-58. PubMed ID: 14593708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [International estimation of molecular target drug].
    Fujisaka Y; Saijo N
    Nihon Rinsho; 2004 Jul; 62(7):1225-31. PubMed ID: 15283137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases.
    Low PS; Henne WA; Doorneweerd DD
    Acc Chem Res; 2008 Jan; 41(1):120-9. PubMed ID: 17655275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A target or a demi-target.
    Mok TS
    Clin Lung Cancer; 2010 May; 11(3):147-8. PubMed ID: 20439189
    [No Abstract]   [Full Text] [Related]  

  • 35. Is there a future for Aurora kinase inhibitors for anticancer therapy?
    Carpinelli P; Moll J
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy.
    Dou QP; Smith DM; Daniel KG; Kazi A
    Prog Cell Cycle Res; 2003; 5():441-6. PubMed ID: 14593738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Molecular-target drug].
    Sone S; Yano S; Nishioka Y
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1034-40. PubMed ID: 15272581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
    Kaye SB
    Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving the evaluation of new cancer treatments: challenges and opportunities.
    Rothenberg ML; Carbone DP; Johnson DH
    Nat Rev Cancer; 2003 Apr; 3(4):303-9. PubMed ID: 12671669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of tumor size response metrics to predict survival in oncology clinical trials.
    Bruno R; Mercier F; Claret L
    Clin Pharmacol Ther; 2014 Apr; 95(4):386-93. PubMed ID: 24419563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.